ノヴォ・ノルドスクの口服用減量錠剤Amycretinは,高用量試験で13%の減量を示し,プラセボでは1%であった. Novo Nordisk's Amycretin oral weight loss pill demonstrated 13% weight loss in high-dose trials, compared to 1% with a placebo.
Novo Nordiskの口服減量錠剤であるAmycretinは,初期試験で有望な結果を示し,低用量で10. 4%,高用量で12週間で13%以上の減量をもたらしました. Novo Nordisk's oral weight loss pill, Amycretin, has shown promising results in early trials, leading to a 10.4% weight loss at a low dose and over 13% at a higher dose over 12 weeks. これはプラセボで 1% の損失と好意的に比較されます. This compares favorably to a 1% loss with a placebo. GLP-1とアミリンホルモン受容体をターゲットにすることで,Amycretinは肥満に対する新しい,より手頃な治療法を提供できる. Targeting GLP-1 and amylin hormone receptors, Amycretin may offer a new, more accessible treatment for obesity. 試験は進行中であり,結果は今年中に発表される予定です. Larger trials are underway, with results expected later this year.